NBW Capital LLC Buys 966 Shares of STERIS plc (NYSE:STE)

NBW Capital LLC lifted its stake in shares of STERIS plc (NYSE:STE) by 3.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 29,105 shares of the medical equipment provider’s stock after purchasing an additional 966 shares during the quarter. NBW Capital LLC’s holdings in STERIS were worth $6,390,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in STE. Russell Investments Group Ltd. grew its position in STERIS by 8.3% during the first quarter. Russell Investments Group Ltd. now owns 58,841 shares of the medical equipment provider’s stock worth $13,235,000 after buying an additional 4,494 shares in the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of STERIS by 3.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 106,346 shares of the medical equipment provider’s stock worth $23,909,000 after purchasing an additional 3,342 shares during the last quarter. Caden Capital Partners LP increased its position in shares of STERIS by 80.0% in the fourth quarter. Caden Capital Partners LP now owns 82,312 shares of the medical equipment provider’s stock worth $18,096,000 after purchasing an additional 36,576 shares during the last quarter. Diversify Advisory Services LLC purchased a new stake in STERIS in the first quarter valued at approximately $903,000. Finally, Perpetual Ltd lifted its position in STERIS by 9.3% during the first quarter. Perpetual Ltd now owns 40,571 shares of the medical equipment provider’s stock valued at $9,121,000 after purchasing an additional 3,437 shares during the last quarter. Institutional investors own 94.69% of the company’s stock.

Insider Activity

In related news, CFO Michael J. Tokich sold 23,332 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the sale, the chief financial officer now owns 42,930 shares of the company’s stock, valued at $10,603,710. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the transaction, the chief financial officer now directly owns 42,930 shares in the company, valued at approximately $10,603,710. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christopher S. Holland sold 473 shares of the firm’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the sale, the director now directly owns 582 shares of the company’s stock, valued at $139,493.76. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Analyst Ratings Changes

STE has been the topic of a number of research reports. JMP Securities restated a “market outperform” rating and set a $265.00 price target on shares of STERIS in a research report on Wednesday, August 7th. Stephens restated an “overweight” rating and issued a $260.00 target price on shares of STERIS in a research report on Wednesday, August 7th. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research report on Thursday, August 8th. StockNews.com upgraded shares of STERIS from a “hold” rating to a “buy” rating in a report on Tuesday, August 13th. Finally, KeyCorp increased their target price on shares of STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a report on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $246.00.

STERIS Stock Down 0.5 %

Shares of NYSE STE opened at $238.24 on Wednesday. The company has a market cap of $23.50 billion, a price-to-earnings ratio of 62.37 and a beta of 0.83. The company has a quick ratio of 1.49, a current ratio of 2.33 and a debt-to-equity ratio of 0.35. The firm’s fifty day moving average is $236.85 and its 200 day moving average is $225.58. STERIS plc has a 52 week low of $195.47 and a 52 week high of $248.24.

STERIS (NYSE:STE) last issued its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating the consensus estimate of $1.98 by $0.16. The firm had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.27 billion. STERIS had a net margin of 7.36% and a return on equity of 13.85%. The company’s quarterly revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.00 earnings per share. On average, equities research analysts expect that STERIS plc will post 9.05 earnings per share for the current year.

STERIS Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 20th. Stockholders of record on Thursday, September 5th were given a $0.57 dividend. This is a positive change from STERIS’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date was Thursday, September 5th. STERIS’s dividend payout ratio (DPR) is currently 59.69%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.